Injectable vitamin B-complex products recalled for lack of sterility assurance
Pharmacy Innovations is recalling three injectable vitamin B-complex products nationwide due to insanitary conditions discovered during FDA inspection. The products lack assurance of sterility and may pose contamination risk.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II recall involving lack of sterility assurance in injectable drugs—a high-risk product category. No illnesses or injuries have been reported. The hazard is based on insanitary conditions discovered during inspection that create potential for contamination, placing this in the High category per the rubric criterion: risk-of-harm products where injury has not yet been reported.
Plain-English summary
Pharmacy Innovations is recalling three injectable vitamin B-complex formulations manufactured at its facility in Erie, PA. The recalled products contain B vitamins including thiamine, riboflavin, niacinamide, dexpanthenol, pyridoxine, and in some formulations hydroxycobalamin, methylfolate, or methylcobalamin. All are Rx only.
The recall was initiated due to lack of assurance of sterility. During an FDA inspection, insanitary conditions were discovered at the manufacturing facility that could compromise the sterility of injectable products.
The affected products were distributed nationwide. The specific lot codes subject to recall are t20221116@36, t20221121@42, and t20221021@32.
The recalled product
- Product
- THIAMINE/RIBOFLA/NIACINAMI/DEXPANTH/PYRIDOX/HYDROXYCOBAL 25MG/25MG/25MG/25MG/25MG/20MG/ML (3ML VIAL) INJECTABLE THIAMINE/RIBOFLA/NIACINAMI/DEXPANTH/PYRIDOX/METHYLFOLATE/METHYLCOBAL 10MG/2.5MG/25MG/5MG/5MG/10MG/10MG/ML (1ML VIAL) INJECTABLE THIAMINE/RIBOFLAVIN/NIACINAMIDE/DEXPANTH
- Manufacturer
- Pharmacy Innovations
- Hazard
- lack-of-sterility
- contamination
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- t20221116@36 t20221121@42 t20221021@32
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27